NCT06336148 - A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 5, 2024

Primary Completion Date

August 28, 2025

Study Completion Date

August 28, 2025

Conditions

Solid Tumor

Interventions

DRUG

ACTM-838

Escalating doses of ACTM-838 in Part 1a and recommended dose in Part 1b

Trial Locations (5)

Westmead Hospital, Cnr Hawkesbury Road and Darcy Road, Site No: 200, Westmead

Alfred Hospital, 55 Commercial Road, Site No: 201, Melbourne

Southern Oncology Clinical Research Unit, Level 3, Mark Oliphant Building, 5 Laffer Drive, Site No: 202, Bedford Park

UPMC Hillman Cancer Center, 5115 Centre Ave, Pittsburgh

University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Ave., Los Angeles